Clinical trials
Progression clinical trials
Below are recruiting progression clinical trials, each written for real people, not researchers. We’re tracking 719 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06311708Recruiting
PKP2-related heart condition natural history study
This study looks at how plakophilin 2 (PKP2)-related arrhythmogenic right ventricular cardiomyopathy (ARVC) progresses over time. You'll give blood samples to check for antibodies to a virus used in gene therapy, and help doctors understand the disease better.
San Francisco, CaliforniaAges 14–65 - NCT07678684RecruitingPhase 2
Study of HF1K16 plus bevacizumab for recurrent glioma
This trial tests a new combination of two drugs, HF1K16 and bevacizumab, for people whose glioma has come back or grown after prior treatment. It aims to see if this combination can help when standard options are no longer working or tolerable.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06335836Recruiting
Social connections and brain health in memory decline
This study looks at how being socially isolated or socially active affects memory and brain health in people who feel their thinking is getting worse. You may join if you notice a slow decline in memory or thinking, but otherwise have normal test results.
Nanjing, China, JiangsuAges 45–85 - NCT06344000Recruiting
Nutrition and disease progression in bronchiectasis
This study looks at how nutrition affects the course of bronchiectasis, a lung condition that causes coughing and frequent infections. It may help find ways to slow the disease down.
Wuhan, HubeiAges 18–100 - NCT06351670Recruiting
Monitoring early to moderate age-related macular degeneration with AI
This study uses artificial intelligence to track changes in the eyes of people with early or intermediate age-related macular degeneration (AMD). It aims to better understand how the disease progresses and may help doctors personalize care.
ViennaAges 55–99 - NCT06351657Recruiting
Monitoring macular degeneration with AI to detect progression
This trial uses artificial intelligence to track changes in the eyes of people with advanced age-related macular degeneration (AMD) that has caused a specific type of damage (atrophy) in the retina. The goal is to see if AI can help detect when the disease gets worse, so doctors can personalize monitoring for each patient.
ViennaAges 55–99 - NCT06356883RecruitingPhase 2
Two chemo combos for progressing glioblastoma
This trial tests two different combinations of chemotherapy drugs given directly into the artery that feeds the brain tumor. It is for people with glioblastoma (a type of brain tumor) that has continued to grow after standard treatment.
Sherbrooke, QuebecAges 18 years+ - NCT06362694RecruitingPhase 2
Re-treating anaplastic thyroid cancer that progressed on BRAF therapy
This trial tests if a second course of targeted therapy (dabrafenib and trametinib) combined with chemotherapy can help people with a specific type of aggressive thyroid cancer (BRAF-positive anaplastic thyroid cancer) whose tumors stopped responding to initial targeted therapy.
Saint PetersburgAges 18 years+ - NCT06374108Recruiting
Resistance training and walking in multiple sclerosis
This study tests whether resistance training (like lifting weights) can improve how your brain and muscles communicate, and whether that helps your walking. It's designed for people with MS who have some walking difficulties.
Aarhus, Central JutlandAges 18 years+ - NCT06380842Recruiting
Organ function after necrosectomy for pancreatitis with sepsis
This study looks at how a surgery to remove dead tissue from the pancreas (called open necrosectomy) affects organ function in patients with acute pancreatitis and sepsis. It may help doctors understand how to better treat this serious condition.
Chengdu, ChinaAges 18 years+ - NCT06387017Recruiting
Can blood tests improve lung cancer screening in smokers with artery disease?
This study looks at whether certain blood tests can help find lung cancer early in people who have smoked for a long time and also have artery disease. The goal is to see if adding these tests to current screening methods can better identify those at highest risk.
MarseilleAges 45–80 - NCT06389110RecruitingPhase 3
Low-dose atropine drops to slow children's nearsightedness
This study tests whether a very low-dose atropine eye drop (0.01%) can safely slow down worsening nearsightedness in children. It is for kids ages 3 to 12 who are already nearsighted but haven't used other myopia control treatments before.
Mexico CityAges 3–12 - NCT06390930Recruiting
Breathing bursts of lower oxygen for hand function in MS
This study tests whether breathing short bursts of reduced oxygen (acute intermittent hypoxia) can improve hand function and nerve health in people with relapsing-remitting MS who have some hand weakness.
Chicago, IllinoisAges 18–75 - NCT06394674RecruitingPhase 2
High-dose furmonertinib for lung cancer after osimertinib stops working
This trial tests a higher dose of a targeted therapy called furmonertinib for people with advanced lung cancer that has stopped responding to a previous drug called osimertinib. It may help if you have a certain EGFR mutation and your cancer has grown outside the brain.
ShanghaiAges 18–75 - NCT06397677Recruiting
Study of Progressive RA Interstitial Lung Disease
This study is looking at people with rheumatoid arthritis (RA) who also have interstitial lung disease (ILD), a condition that causes scarring in the lungs. It aims to understand how the disease changes over time by using imaging and blood tests, without providing any new treatments right now.
San Francisco, CaliforniaAges 18–90 - NCT06413459Recruiting
New markers for lung disease in cystic fibrosis
This study looks for biological markers (substances in your body) that can show if a lung infection with Mycobacterium abscessus is getting worse. It may help researchers develop better ways to track and treat the infection in people with cystic fibrosis.
Milan, MIAges 18 years+ - NCT06416761Recruiting
Genetics and kidney disease progression study
This study looks at how genetics affect the progression of kidney diseases. Joining may help researchers understand your condition better and find better treatments.
MilanAges 18 years+ - NCT06435000Recruiting
A study tracking Stargardt disease progression
This study follows people with Stargardt disease (a genetic eye condition that causes vision loss) over time. It aims to learn more about how the disease progresses and does not test any treatment.
San Diego, CaliforniaAges 12–65 - NCT06439836RecruitingPhase 1
Combination immunotherapy for advanced bladder cancer
This trial tests a new drug, CA-4948, combined with pembrolizumab (Keytruda) for people with advanced bladder cancer that grew after prior immunotherapy. The goal is to see if this combination can help when standard treatments stop working.
Duarte, CaliforniaAges 18 years+ - NCT06440746RecruitingPhase 2/Phase 3
Testing olokizumab for progressive lung scarring diseases
This trial tests a drug called olokizumab to see if it can slow down worsening lung scarring (fibrosis) in people with certain types of progressive interstitial lung diseases. It's for patients whose lung function has declined despite current treatments.
BarnaulAges 18 years+ - NCT06446531RecruitingPhase 1
Preventing diabetes progression in Hispanic adults
This trial tests if a medication can prevent or slow the progression from prediabetes to type 2 diabetes and reduce heart risk. It is for Hispanic adults who are overweight and have prediabetes.
San Antonio, TexasAges 18 years+ - NCT06452550Recruiting
Can brain scans predict Crohn's disease progression?
This study uses brain MRI and psychological questionnaires alongside standard Crohn's tests to see if certain brain patterns predict how the disease will progress over six months or more.
ShanghaiAges 18–45 - NCT06456814Recruiting
Study on how brain aneurysms form, grow, and rupture
This study looks at medical records from multiple hospitals in China to understand how brain aneurysms develop and when they might rupture. It may help researchers find better ways to predict and treat them.
GuangzhouAges 18–80 - NCT06464042Recruiting
Air Quality and Early Heart Disease Study
This trial studies how air quality affects early heart disease in young adults aged 18 to 40. It looks at people in Galicia, Spain, who already have coronary artery disease and compares them to healthy individuals.
Vigo, PontevedraAges 18–40
Hear when a new Progression trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for progression?
- Yes. Clin2 currently lists 719 recruiting progression studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a progression trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a progression trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.